camilla porta

Mrs. camilla porta

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Lung Cancer
Verified
Journal Article
Closed access
CPcamilla porta
camilla porta
LPLorenzo Pradelli
Lorenzo Pradelli
ESEmilia Sicari
Emilia Sicari
SCSilvia Castellani
Silvia Castellani
SSSmruthy Sivakumar
Smruthy Sivakumar
MTMarcello Tiseo
Marcello Tiseo

HHHirad Houshmand
Hirad Houshmand
CPcamilla porta
camilla porta
LPLorenzo AdRes PRADELLI
Lorenzo AdRes PRADELLI
MPMatteo Pinciroli
Matteo Pinciroli
Giovanni SotgiuGiovanni Sotgiu
Giovanni Sotgiu
Background: We aimed to estimate the economic and clinical impacts of a novel diagnostic test called LIAISON® MeMed BV® (LMMBV), which can differentiate bacterial from viral infections, in patients with community-acquired pneumonia (CAP) in emergency departments. Methods: A cost-impact simulation model was developed to investigate the financial consequences of the introduction of LMMBV into the standard of care (SOC) diagnostic process in Italy, Germany, and Spain. Clinical outcomes were expressed as antibiotic patients and days saved, reduced hospital admissions, and shortened hospital length of stay (LOS). Cost savings were evaluated from the perspectives of third-party payers and hospitals. A deterministic sensitivity analysis (DSA) was carried out. Results: LMMBV was associated with a reduction in antibiotic prescriptions, treatment duration, and LOS. Furthermore, the adoption of LMMBV would allow savings per patient up to EUR 364 and EUR 328 for hospitals and EUR 91 and EUR 59 for payers in Italy and Germany, respectively. In Spain, average savings per patient could reach up to EUR 165 for both payers and hospitals. Savings were most sensitive to test accuracy, with DSA confirming the robustness of the results. Conclusions: Combining LMMBV with the current SOC diagnostic process is expected to provide clinical and economic benefits in Italy, Germany, and Spain.

29 October 2025 in ESMO Open
Verified
Journal Article
Open access
FSFrancesca Salani
Francesca Salani
FPFrancesca Romana Ponziani
Francesca Romana Ponziani
FPF. Piscaglia
F. Piscaglia
UMU. Malapelle
U. Malapelle
BDBruno Daniele
Bruno Daniele
AGA. Casadei Gardini
A. Casadei Gardini
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, with limited molecular characterization due to reliance on radiological diagnosis. This study aims to characterize the genomic landscape of advanced HCC and assess the prognostic and predictive roles of genetic alterations (GAs). This study used a de-identified nationwide (USA-based) HCC clinico-genomic database to retrospectively analyze patients with advanced HCC who received systemic therapies and underwent comprehensive genomic profiling via tissue or liquid biopsy. GAs were identified using Foundation Medicine, Inc.'s next-generation sequencing tests. Time to progression (TTP) was assessed using Kaplan-Meier analysis and Cox proportional hazards models. In total, 370 patients were analyzed. The most frequent GAs in the tissue cohort (n = 291) involved TERT promoter (TERTp, 61.5%), CTNNB1 (34.0%), and TP53 (33.0%). Key affected pathways were cell cycle and apoptosis (56%), DNA damage and control (43%), WNT (40.9%), and p53 (38.1%). Viral etiology was significantly associated with alterations in TERTp, CTNNB1, and the WNT pathway, while non-viral HCC was associated with alterations in the RTK/RAS pathway. TTP analysis revealed a trend toward improved outcomes with atezolizumab + bevacizumab (A + B) compared with tyrosine kinase inhibitors. TP53, p.V157F, and p.R249S mutations were associated with significantly shorter TTP. MYC seemed to be a negative predictor for A + B versus tyrosine kinase inhibitors, but statistical significance was not reached. This study highlights the genomic landscape of advanced HCC, identifying cell cycle and apoptosis, DNA damage and control, WNT, and p53 as the key affected pathways. Further research is warranted to confirm such findings.

30 June 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
CPcamilla porta
camilla porta
HHHirad Houshmand
Hirad Houshmand
MPMassimiliano Povero
Massimiliano Povero
LPLorenzo AdRes PRADELLI
Lorenzo AdRes PRADELLI
FMFilippo Monterosso
Filippo Monterosso
JCJuan González del Castillo
Juan González del Castillo
In a randomized control trial mid-regional proadrenomedullin (MR-proADM)-guided decision-making has been proven to safely reduce hospital admissions based on an accurate assessment of disease severity in the Emergency Department (ED). This study aimed to assess the impact of a MR-proADM-Guided Triage (MR-GT) versus standard Hospital Triage (HT) on clinical and economic outcomes in ED patients with suspected infection in Spain, Italy, Germany, and the UK, using Patient-Level Data (PLD) from two observational studies. PLD was collected from patients enrolled at a Spanish hospital during two observational studies. Logistic regression was used to identify predictors of hospitalization. A patient-level simulation model was subsequently developed to evaluate the clinical and economic impact of MR-GT versus HT using results from the statistical analysis and country-specific cost data from the published literature. Probabilistic and deterministic sensitivity analyses were carried out. Four hundred seventy-three patients were enrolled in this study. MR-proADM had the strongest association with hospital admission, followed by age and National Early Warning Score (NEWS). In the simulation model, MR-GT was associated with an overall reduction in unnecessary hospitalization relative to HT, equal to 22.6 percentage points (40.9% vs 63.5%). In addition, the use of MR-GT would reduce the total hospital cost per patient presenting to the ED with suspected infection by roughly 30%, with a mean cost saving per patient of €626, €1,484, €1,154, and £1,113 in Spain, Italy, Germany, and the UK respectively. The robustness of these findings was confirmed by sensitivity analyses. The statistical analyses were not performed on the same population simulated in the model. Clinical input parameters were assumed to be the same for all countries. MR-proADM showed to be the main predictor of hospitalization. A MR-proADM decision algorithm provides cost savings in Spain, Italy, Germany, and the UK.

17 February 2026 in Journal of Medical Economics
Verified
Journal Article
Open access
CPcamilla porta
camilla porta
LPLorenzo AdRes PRADELLI
Lorenzo AdRes PRADELLI
GCGiovanni Cirotto
Giovanni Cirotto
MMMaria Teresa Majorini
Maria Teresa Majorini
OGOsvaldo Ulises Garay
Osvaldo Ulises Garay
PLPietro Lampertico
Pietro Lampertico
Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin K absence-II [PIVKA-II]) demonstrated good performance for the detection of early-stage HCC. This study aimed to assess the cost-effectiveness of the GAAD algorithm for HCC surveillance in patients with CC in Italy, from the Italian Health Service perspective. A probabilistic micro-simulation Markov model was adapted to the Italian context to estimate lifetime clinical outcomes and costs of CC patients undergoing bi-annual surveillance with ultrasound (US), US+AFP, GAAD, and US+GAAD. Clinical inputs and utility values were derived from Italian real-world data and published literature. Direct healthcare costs were collected from Italian sources. Costs and outcomes were discounted at an annual 3% rate. Sensitivity analyses were conducted to evaluate the uncertainties in input parameters. In a simulated cohort of 100,000 CC patients, QALYs and costs per patient were 6.53 and €35,524 for US, 6.56 and €35,825 for US+AFP, 6.57 and €35,423 for GAAD, and 6.58 and €35,939 for US+GAAD. Compared to US and US+AFP, GAAD was dominant, while US+GAAD was cost-effective (ICUR of €9,482 and €10,951 per QALY gained, respectively). At a willingness-to-pay threshold of €30,000, GAAD was the most cost-effective strategy. Sensitivity analyses confirmed the robustness of results. Assumptions were required to estimate the diagnostic performance of US+GAAD, given the absence of prospective validation data. Some clinical parameters were derived from non-Italian sources, which may limit generalizability. GAAD, alone or combined with US, is a cost-effective strategy for HCC surveillance in CC patients in Italy, improving the detection of early-stage disease. Better performance data for US+GAAD is needed to confirm results.

3 August 2026 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
CPcamilla porta
camilla porta
PPPaolo Di Procolo
Paolo Di Procolo
GMGiuseppina Marrazzo
Giuseppina Marrazzo
MBMarco Belfiore
Marco Belfiore
RPRaffaele Palladino
Raffaele Palladino
MMMarcello Moccia
Marcello Moccia
Objectives The aim of this study was to evaluate the budget impact of introducing the subcutaneous (SC) form of ocrelizumab for patients with relapsing forms of multiple sclerosis (RMS) with high disease activity (HA) despite previous treatment or with rapidly evolving severe (RES) disease in Italy from the hospital perspective. Methods A 3-year dynamic budget impact model with a Markov structure was developed de novo to simulate patient transitions across Expanded Disability Status Scale–defined health states. The current scenario (without ocrelizumab SC) was compared with an alternative scenario reflecting expected ocrelizumab SC uptake. Number of eligible patients reflected Italian population and projected market shares. Efficacy inputs were obtained from published literature, with adherence and persistence sourced from Italian real-world data. Unit costs—including drug administration, monitoring, adverse events, disease management, and relapse—were collected from Italian sources. Drug acquisition costs were considered in a scenario analysis. Parameter uncertainty was explored through deterministic sensitivity and scenario analyses. Results Over 3 years, 22,128 patients were eligible, of whom 5389 were assumed to receive ocrelizumab SC. Ocrelizumab SC introduction would generate cumulative savings of about €2.0 million, mainly from reduced administration and monitoring costs, with additional savings from relapse and disease management expenditures. When drug acquisition costs were included, total savings rose to roughly €7.1 million. Sensitivity analyses confirmed the robustness of these findings. Conclusions Ocrelizumab SC may be a cost-saving and resource-efficient option for HA/RES RMS management in Italy. By reducing administration time while maintaining the established clinical profile of the intravenous (IV) formulation of ocrelizumab, its adoption can enhance hospital efficiency and deliver meaningful budgetary savings.